

References

References

- Abbott JA, Garry R.** The surgical management of menorrhagia. Hum. Reprod. Update 2002; 8 (I): 68-78.
- ACOG.** practice bulletin: Intrauterine device. Int. J. Gynaecol. Obstet. 2005; 105:223-32.
- ACOG** practice bulletin : management of anovulatory bleeding . Int. J. Gynaecol. Obstet . 2001; 72: 263- 271.
- Ahmed A, Smith SK.** Platelet-activating factor stimulates phospholipase C activity in human endometrium. J. Cell Physiol. 1992; 152: 207-214
- Alecozay AA, Delon FD, Harper MJ et al.** Platelet activating factor (PAF) in human endometrium. Bio. Reprod. 1988; 38 (suppl. I): 78
- Alecozay AA, Harper MJ, Schenken RS, et al.** Paracrine interactions between platelet activating factor and prostaglandins in hormonally treated luteal phase endometrium. J. Reprod. Fertil. 1991; 91:301-12.
- Andersson K.** The levonorgestrel intrauterine system: more than a contraceptive. Eur. J. Contracept. Reprod. Health Care 2001; 6 (I): 15-22.
- Andersson K, Batar I, Rybo G.** Return to fertility after removal of a levonorgestrel-releasing intrauterine device and Nova-T. Contraception. 1992;46:575-584.

- Andersson K, Odland V, Rybo G.** Levonorgestrel releasing and copper releasing (Nova T) IUD's during five years of use: a randomized comparative trial. *Contraception* 1994; 49: 56-72.
- Andersson K, Ryde E, Lindell K, et al.** Perforations with intrauterine devices. Report from a Swedish survey. *Contraception*. 1998;57:251-255.
- Andersson JK, Rybo G.** Levonorgestrel-releasing intrauterine device in treatment of menorrhagia. *Br. J. Obstet. Gynaecol.* 1990; 97: 690-694.
- Archer D, Kovacs L, Landgren BM, et al.** Implanon, a new single-rod contraceptive implant; presentation of clinical data. *Contraception* 1998; 58: 75-115.
- Archer DF, Viniestra A, Hsiu JG, et al.** Endometrial histology, uterine bleeding and metabolic changes in postmenopausal women using progesterone releasing intrauterine device and oral conjugated oestrogens for hormonal replacement therapy. *Menopause* 1994; 1:109-116.
- Azam ME, Kamal MM, Wafa GA, et al.** Treatment of menorrhagia with intrauterine administration of levonorgestrel. *Egypt. J. Fertil. Steril.* 1998; 2 (2): 55-64.
- Azziz R.** Adenomyosis: current perspective. *Obstet. Gynecol. Clin. North Am.* 1989; 16(1); 221-235
- Backman T, Huhtala S, Luoto R, et al.** Advance information improves user satisfaction with the levonorgestrel intrauterine system. *Obstet. Gynecol.* 2002;99:608-613.

- Baldwin RM, Whalley PJ, Pritchard JA.** Measurement of menstrual blood loss. *Am. J. Obstet. Gynecol.* 1961; 81:739-42.
- Barbosa I, Olsson SE, Odland V, et al.** Ovarian function after seven years use of a levonorgestrel IUD. *Adv. Contraception.* 1995; 11: 85 –95.
- Barrington JW, Bowen SP.** The levonorgestrel intrauterine system in the management of menorrhagia. *Br. J. Obstet. Gynaecol.* 1997; 104 (5): 614-6.
- Baveja R, Bichille LK, Coyaji KJ, et al.** Randomized clinical trial with intrauterine devices (levonorgestrel intrauterine device (LNG), CuT 380Ag, CuT 220C and CuT 200B). A 36-month study. Indian Council of Medical Research Task Force on IUD. *Contraception.* 1989;39:37-52.
- Bayer S, De Cherney AH.** Clinical manifestations and treatment of dysfunctional uterine bleeding. *Am. J. Obstet. Gynecol.* 1993; 269:1823-8.
- Bjork J, Smedegard G.** Acute microvascular effects of PAF-acether, as studied by intravital microscopy. *Eur. J. Pharmacol.* 1983; 96: 87-94
- Blesey EM.** Vaginal bleeding patterns among women using one natural and eight hormonal methods of contraception. *Contraception* 1988; 38:186-206.
- Bonduella M, Walker JJ, Calder AA.** A comparative study of danazol and norethisterone in dysfunctional uterine bleeding presenting as menorrhagia. *Postgrad. Med. J.* 1991; 67:833-6.

Bonnar J, Sheppard BL. Treatment of menorrhagia during menstruation: randomized controlled trial of ethamsylate, mefenamic acid, and tranexamic acid. *Br. Med. J.* 1996; 313:579-82.

Bonnar J, Sheppard BL, Dockeray CJ. The haemostatic system and dysfunctional uterine bleeding. *Res. Clin. Forum.* 1983; 5: 27-36

Bouyer J, Rachou E, Germain E, et al. Risk factors for extrauterine pregnancy in women using an intrauterine device. *Fertil. Steril.* 2000; 74: 899-908.

Brechin S, Cameron ST, Paterson AM, et al. Intrauterine polyps a cause of unscheduled bleeding in women using Levonorgestrel intrauterine system: Case report. *Hum. Reprod.* 2000; 15 (3): 650-2.

Bren L. Alternatives to hysterectomy: New Technologies, more options. *FDA Consum* 2001;35:23-8. 30.

Brown PM, Farquhar CM, Lethaby A, et al. Cost-effectiveness analysis of levonorgestrel intrauterine system and thermal balloon ablation for heavy menstrual bleeding. *Br. J. Obstet. Gynaecol.* 2006; 113:797-803.

Burhank F and Hutchins J. Uterine artery occlusion by remobilization or surgery for treatment of fibroids: A unifying hypothesis transient uterine ischemia. *J. Am. Assoc. Gynecol. Laparosc.* 2000; 4: SI-S49.

Busfield RA, Farquhar CM, Sowter MC, et al. A randomised trial comparing the levonorgestrel intrauterine system and thermal

balloon ablation for heavy menstrual bleeding. Br. J. Obstet Gynaecol. 2006; 113:257-263.

Bussolat B, Dunk C, Grohman M, et al. Vascular endothelial growth factor receptor-1 modulates vascular endothelial growth factor mediated angiogenesis via nitric oxide. Am. J. Pathol. 2001; 159:993-1008.

Butler WJ. Normal and abnormal uterine bleeding. In: Thompson JD, Rock JD (Eds), Textbook of Operative Gynecology, 8th Edition, Philadelphia : Lippincott-Raven publisher 1997; 453 -475.

Caliskan E, Ozturk N, Dilbaz BO, et al. Analysis of risk factors associated with uterine perforation by intrauterine devices. Eur. J. Contracept. Reprod. Health Care. 2003;8:150-155.

Cameron I, Davenport A, Brown J, et al. Endothelin-1 stimulates prostaglandin F_{2α} release from human endometrium. Prostaglandins 1991; 42:155-7.

Cameron I, Davenport A, Papendorp VC. Endothelin-like immunoreactivity in human endometrium. J. Reprod. Fertil. 1995; 95:623-8.

Cameron IT. Dysfunctional uterine bleeding and menorrhagia. Clin. Obstet. Gynaecol. 1989; 3: 315-327.

Cameron IT. The levonorgestrel intrauterine system: the benefits of reduced bleeding. Eur. J. Contracept. Reprod. Health Care 2001; 6 (I):27-32.

Cameron IT, Haining R, Lumbsden AJ et al. The effects of mefenamic acid and norethisterone on measured menstrual blood loss. Obstet. Gynecol. 1990; 96: 85-88.

Cameron IT, Leask R, Kelly RW. The effects of danazol, mefenamic acid, norethisterone, and a progesterone impregnated coil on endometrial prostaglandin concentrations in women with menorrhagia. *Prostaglandins* 1987; 34:99-110.

Cameron IT. Menstrual disorders. In: Edmonds DK (ed), Dewhurst's Text Book of Obstetrics and Gynaecol for Postgraduate. 6th Edition. Scientific Publication, Oxford London 1999: 410-19.

Cameron IT, Norman JE. Endometrial biochemistry in menorrhagia. *Porg. Report. Med.* 1995; 2: 267-79

Campagnoli C, Lesca L, peris C. Long term hormone replacement treatment in menopause. *Lancet* 1993 ; 18 (1): 21-46.

Camussi G, Aglietia M, Malavas F. The release of platelet- activating factor from human endothelial cells in culture. *J. Immunol.* 1983; 131: 2397-2403

Carter CF. Endometrial ablation: more choices, more options. *Hum. Reprod.* 2005; 30:35-40.

Casey M L, Hemsell D L, MacDonald P C, et al. NAD⁺dependent 15-hydroxy-prostaglandin dehydrogenase activity in human endometrium. *Prostaglandins* 1980; 19:115-122

Celik H, Sapmaz E. Use of a single preoperative dose of misoprostol is efficacious patients who undergo abdominal myomectomy. *Fertil. Steril.* 2003; 79(5): 1207-10.

Chapman DR, Key SM, Ryam JM. Uterine artery embolization for the treatment of symptomatic fibroid disease. *Applied Radiology* 2001; 11-17.

Charnock JD, Sharkey AM, Rajpu J, et al. Identification and localization of alternately spliced mRNAs for vascular endothelial growth factor in human uterus and estrogen regulation in endometrial carcinoma cell lines. *Biol. Reprod.* 1993; 48:1120-28.

Cheng, L, Kelly RW, Thong KJ et al. The effects of mifepristone (RU 486) on prostaglandin dehydrogenase in decidual and chorionic tissue in early pregnancy. *Hum. Reprod.* 1993; 8:705-509.

Chimbira TH, Anderson AB, Turnbull AC. Relation between measured loss and the patient's subjective assessment of loss, duration of bleeding, number of sanitary towels used, uterine weight and endometrial surface area. *Br. J. Obstet. Gynaecol.* 1980a; 87: 603-609

Chimbira TH, Anderson AB, Naish C, et al. Reduction of menstrual blood loss by danazol in unexplained menorrhagia: lack of effect of placebo. *Br. J. Obstet. Gynaecol.* 1980b; 87:1152-8.

Chrisman C, Ribeiro P, Dalton VK. **The levonorgestrel releasing intrauterine system: An updated review of the contraceptive and noncontraceptive uses.** *Clin. Obstet. Gynecol.* 2007;50(4):886-897.

Christiaens GC, Sixma JJ, Haspels AA. Hemostasis in menstrual endometrium: a review. *Obstet. Gynecol. Survey* 1982; 37:281.

Christiaens GC, Sixma JJ, Haspels AA. Morphology of haemostasis in menstrual endometrium. *Br. J. Obstet. Gynaecol.* 1980; 87: 425-430

- Christiaens GC, Sixma JJ, Haspels AA.** Fibrin and platelets in menstrual discharge before and after the insertion of an intra-uterine contraceptive device. *Am. J. Obstet. Gynecol.* 1981; 140: 793-798.
- Clarke A, Black N, Rowe P, et al.** Indications for and outcome of total abdominal hysterectomy for benign disease: A prospective cohort study. *Br. J. Obstet. Gynaecol.* 1995; 102:611-20.
- Cohen I.** Levonorgestrel releasing intrauterine device. *Lancet* 2001; 357: 801-805.
- Cohen MA.** Anaemia and menstrual blood loss. *Obstet. Gynecol. Surv.* 1980; 35: 597-601.
- Coleman M. Me Cowen L, Farquhar C.** The levonorgestrel releasing intrauterine device: a wider role than contraception. *Am. J. Obstet. Gynecol.* 1997;37 (2): 195-201.
- Cole SK, Billewicz WZ, Thomson AM.** Sources of variation in menstrual blood loss. *J. Obstet. Gynaecol. Br. Commonw* 1971; 78: 933-939.
- Collaborative Group on hormonal factors in Breast cancer.** Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53,297 women with breast cancer and 100,293 women without from 54 epidemiological studies. *Lancet* 1996; 347:1713-1727.
- Cooke I, Lethaby A, Farquhar C.** Antifibrinolytics for heavy menstrual bleeding (Cochrane Review). *The Cochrane Library*, Issue 4, 2000. Oxford: Update Software.
- Cooper JM, Erickson ML.** Global endometrial ablation technologies. *Obstet. Gynecol. Clin. North Am.* 2000; 27:385-96.

- Cooper KG, Parkin DE, Garnet AM, et al.** Two-year follow up of women randomized to medical management or transcervical resection of the endometrium for heavy menstrual loss: clinical and quality of life outcomes. *Br. J. Obstet. Gynaecol* 1999; 106:258-65.
- Coulter A, Broadlow J, Agass M, et al.** Outcomes of referrals to gynaecology out-patient clinics for menstrual problems: An audit of general practice records. *Br. J. Obstet. Gynaecol.* 1991; 98:789-96.
- Coulter A.** Prevalence and epidemiology of dysfunctional uterine bleeding. In: Smith SK (ed) *Dysfunctional uterine bleeding*. London: Royal Society of Medicine Press, 1994; 2-5.
- Critchley HO, Wang H, Jones RL, et al.** Morphological and functional features of endometrial decidualization following long term intrauterine levonorgestrel delivery. *Hum. Reprod.* 1998; 13: 1218-1224.
- Crosignani PG, Rubin B.** Dysfunctional uterine bleeding. *Hum Reprod* 1990; 5:637-8.
- Cunningham FG, Leveno KJ, Bloom SL, et al.** Maternal anatomy, *Williams Obstetrics 22nd Edition*, New York: McGraw- Hill 2005; 23.
- Davey DA.** Dysfunctional uterine bleeding. In: Whitfield CR (ed) *Dewhurst's Text Book of Obstetrics and Gynecology, 5th Edition*, London: Blackwell science 1995; 590-608.
- Davie J.** New hormone delivery systems. *Diplomate* 1996; 3 (3): 184- 190.

- Davis GK, Chapman (Eds).** The menstrual cycle: the physiology of the endometrium in: Scientific foundation of Obstet. and Gynaecol. 4th edition, London: Butterworth-Heinemann LTD 1992; 186-199.
- DeLancey JL.** Surgical anatomy of female pelvis. In: Rock JA and Jones H.W, Eds. TE Linde's Operative Gynecology, 9th edition, Lippincott Williams of Williams, Philadelphia 2003; 69-102.
- De Ziegler D, Bessis R, Frydman R.** Vascular resistance of uterine arteries: physiological effects of estradiol and progesterone. Fertil. Steril. 1991;55:775-9.
- Diaz S, Pavez M, Cardenas H, et al.** Recovery of fertility and outcome of planned pregnancies after the removal of Norplant subdermal implants or Copper-T IUDs. Contraception. 1987;35:569-579.
- Dicker RC, Greenspan JR, Strauss LT, et al.** Complications of abdominal and vaginal hysterectomy among women of reproductive age in the United States. A Collaborative Review of Sterilization. Am. J. Obstet. Gynecol.1982; 144:841-8.
- Doherty LB, Harper A, Russell M.** Menorrhagia management options. Fertil. Steril. 1995; 64:64-71.
- Doll H, Vessey M, Painter R.** Return of fertility in nulliparous women after discontinuation of the intrauterine device: comparison with women discontinuing other methods of contraception. Br. J. Obstet. Gynaecol. 2001;108:304-314.

- Downie J, Poyser N L, Wunderlich M.** Levels of prostaglandins in human endometrium during the normal menstrual cycle. *J. Physiol.* 1974; 236: 465-472
- Drudy L, Sheppard BL, Bonnar J.** Histamine concentration in plasma of menstrual and peripheral blood in patients with normal menstrual blood loss and in dysfunctional uterine bleeding. *Br. J. Obstet. Gynaecol.* 1994; 14:435-7.
- Duenas JL, Albert A, Carrasco F.** Intrauterine contraception in nulligravid vs parous women. *Contraception.* 1996;53:23-24.
- Economos K, MacDonals PC, Casey ML.** Endothelin-1 gene expression and protein biosynthesis in human endometrium: potential modulator of endometrial blood flow. *J. Clin. Endocrinol. Metab.* 1992;74:14.
- Edwards JE, Moore A.** Implanon: a review of clinical studies. *Br. J. fam. Plan.* 1999; 24: 3-16.
- El-Makhzangy IM, Hegab HM, Galal HM, et al.** The effect of rectal misoprostol on menstrual blood loss in menorrhagia. *Egypt. J. Fertil. Steril.* 2003; 7(3): 55-61.
- Erian J.** Endometrial ablation in the treatment of menorrhagia. *Br. J. Obstet. Gynaecol.* 1994; 101(suppl II): 19-22.
- Eroglu K, Akkuzu G, Vural G, et al.** Comparison of efficacy and complications of IUD insertion in immediate postplacental/early postpartum period with interval period: 1 year follow-up. *Contraception.* 2006;74:376-381.

Farley TM, Rosenberg MJ, Rowe PJ, et al. Intrauterine devices and pelvic inflammatory disease: an international perspective. *Lancet*. 1992;339:785-788.

Farquhaw C. Management of dysfunctional uterine bleeding. *Drugs* 1992; 44:578-89.

Farrer BG, Beilby J, Tarbit M. Venous changes in the endometrium of myomatous uteri. *Obstet. Gynecol.* 1971; 38:743- 51.

Fedele L, Bianchi S, Raftaelli R, et al. Treatment of adynomyosis associated menorrhagia with a levonorgestrel releasing intrauterine device. *Fertil. Steril.* 1997; 68: 426-29.

Fedele L, Bianchi S, Zanconato G, et al. Use of a levonorgestrel releasing intrauterine device in the treatment of rectovaginal endometriosis. *Fertil. Steril.* 2001;75:485-488.

Fedorkow DM, Corenblum B, Shaffer EA. The use of gonadotrophin releasing analog and transdermal estrogen to preserve fertility in women with menorrhagia. *Fertil. Steril.* 1989; 52:512-3.

Floridon C, Lund N, Thomsen SG. Alternative treatment for symptomatic fibroids. *Curr. Opin. Obstet. Gynecol.* 2001; 13:491 -5.

Fraser IS. Menorrhagia: a pragmatic approach to the understanding of causes and the need for investigations. *Br. J.Obstet. Gynaecol.* 1994; 101, suppl.11,3-7.

Fraser IS. Hysteroscopy and laparoscopy in women with menorrhagia. *Am. J. Obstet. Gynecol.* 1992; 162; 1264-1269.

- Fraser IS.** Treatment of ovulatory and anovulatory dysfunctional uterine bleeding with oral progestogens. *Br. J. Obstet. Gynaecol.* 1990;30:352-6.
- Fraser IS.** The dysfunctional uterus : dysmenorrhoea and dysfunctional uterine bleeding. In: Shearman RP (ed) clinical reproductive endocrinology. Edinburgh: Churchill Livingstone, 1985: 578-598.
- Fraser IS, Baird DT.** Blood production and ovarian secretion of estradiol-17 β and estrone in women with dysfunctional uterine bleeding. *J. Clin. Endocrinol. Metab.* 1974; 39: 564-570.
- Fraser IS, Hickey M, Song Y.** A comparison of mechanisms underlying disturbances of bleeding due to spontaneous dysfunctional uterine bleeding and to hormonal contraception. *Hum. Reprod.* 1996; 11 (suppl 2): 165-178.
- Fraser IS, McCarron G.** Randomized trial of 2 hormonal and 2 prostaglandin inhibiting agents in women with a complaint of menorrhagia. *Br. J. Obstet. Gynaecol.* 1991; 31:66-70.
- Fraser IS, McCarron G, Markham RA.** Preliminary study of the factors influencing perception of menstrual blood loss volume. *Am. J. Obstet. Gynecol.* 1984; 149: 788-793.
- Fraser IS, McCarron G, Markham R, et al.** Blood and total fluid content of menstrual discharge. *Obstet. Gynecol.* 1985; 65: 194-198.
- French R, Van VH, Cowan F, et al.** Hormonally impregnated intrauterine systems versus other forms of reversible contraceptives as effective methods of preventing pregnancy. *Cochrane Database Syst Rev.* 2004:CD001776.

- Friedman AJ, Harrison Atlas D, Barbieri RL, et al.** A randomized, placebo controlled, double blind study, evaluating the efficacy of leuprolide acetate depot in treatment of uterine leiomyomata. *Fertil. Steril.* 1989; 51:251.
- Galle PC, McRae MA.** Abnormal uterine bleeding. *Postgrad. Med.* 1993,93:73-76.
- Gambrell RD.** Progestogens in oestrogen replacement therapy. *Clin. Obstet. Gynecol.* 1995; 38: 890-901.
- Gannon MJ, Day P, Hammadieh N, et al.** A new method for measuring menstrual blood loss and its use in screening women before endometrial ablation. *Br. J. Obstet. Gynaecol.* 1996; 103 (10):1029-33.
- Gardner FJ, Konje JC, Abrams KR, et al.** Endometrial protection from tamoxifen stimulated changes by a levonorgestrel releasing intrauterine system: a randomised controlled trial. *Lancet.* 2000,356:1711- 1717.
- Garry R.** Good practice with endometrial ablation. *Obstet. Gynecol.* 1995; 85:144-51.
- Garry R, Khair A, Mooney P et al.** A comparison of goserlin and danazol as endometrial thinning agents prior to endometrial laser ablation. *Br. J. Obstet. Gynaecol.* 1996; 103:339-44.
- Garry R and Phillips G.** How safe is the laparoscopic approach to hysterectomy? *Gynaecol. Endosc.* 1995; 4:77-9.

- Gonzalez D, Alvarez RB, Ochoa EP.** Treatment of uterine leiomyomas with luteinizing hormone releasing hormone antagonist Cetrorelix. Hum. Reprod. 1997; 12:2028-35.
- Gosling RG.** Extraction of physiological information from spectrum analysed doppler shifted continuous wave ultrasound signals obtained noninvasively from the arterial tree. In Hill DW and Watson BW (eds). Medial Electronic Monographs 13-22 Peter Peregrinus, London 1979:73-125.
- Graff IS, Tonstad S.** Use of progestogen only contraceptives medications and lipid parameters in women age 40 to 42 years; results of a population based cross sectional Norwegian Survey. Contraception. 2002;66:7.
- Graubert MD, Ortega MA, Kessel B, et al.** Vascular repair after menstruation involves regulation of vascular endothelial growth factor receptor phosphorylation. Am. J. Pathol. 2001; 158:1399-410.
- Grimes DA.** Intrauterine device and upper genital tract infection. Lancet. 2000;356:1013-1019.
- Grimes DA, Schulz KF.** Antibiotic prophylaxis for intrauterine contraceptive device insertion. Cochrane Database Syst Rev. 2001:CD001327.
- Grimes D, Schulz K, Stanwood N.** Immediate postabortal insertion of intrauterine devices. Cochrane Database Syst Rev. 2004:CD001777.
- Grimes D, Schulz K, Van Vliet H, et al.** Immediate post-partum insertion of intrauterine devices. Cochrane Database Syst Rev. 2003:CD003036.

- Grimes DA, Schulz KF.** Prophylactic antibiotics for intrauterine device insertion: A metaanalysis of the randomized controlled trials. *Contraception* 1999; 60: 57-63.
- Grunfeld L.** The uterus and endometrium, vaginal ultrasonography for practicing clinician. *Clin. Obstet. Gynecol.* 1996; 39:175-187.
- Guillebaud J.** Intrauterine contraception-what now and what next? *Eur. J. Contracept. health care* 2001; 1:11-14.
- Gu Z, Zhu P, Luo H, et al.** A morphometric study on the endometrial activity of women before and after one year with levonorgestrel intrauterine system in situ. *Contraception* 1995; 52 (I): 57-61.
- Hagenfeldt K, Landgren BM, Edstrom K, et al.** Biochemical and morphological changes in the human endometrium induced by the progestassert device. *Contraception* 1977; 16: 183-197.
- Hallberg L, Hogdahl A, Nilsson L, et al.** Menstrual blood loss: a population study. *Acta. Obstet. Gynecol. Scand.* 1966; 45: 320-351.
- Hallberg L, Nilsson JL.** Determination of menstrual blood loss. *Scand. J. Clin. Lab. Invest.* 1964; 16:244-8.
- Hart R, Magos A.** The alternatives to hysterectomy. *Clin. Obstet. Gynecol.* 1999; 13:271-90.
- Haspels AA.** Emergency Contraception: a review. *Contraception* 1994; 90: 203-209.

- HTAC.** Surgical alternatives to hysterectomy for abnormal uterine bleeding. Minnesota Health Technology Advisory Committee: 2000 June. Available at: <http://www.health.state.mn.us/htac/sah.htm>.
- Henzl MR, Corson SL, Moghissi K.** Administration of nasal nafarelin as compared to oral danazol for endometriosis. *N. Eng. J. Med* 1988;318:485-9.
- Higham JM, O'Brien PM, Shaw RW.** Assessment of menstrual blood loss using a pictorial chart. *Br. J. Obstet. Gynaecol.* 1990; 97:734-9.
- Higham JM, Shaw RW.** A comparative study of danazol, a regimen of decreasing doses of danazol, and norethindrone in the treatment of objectively proven unexplained menorrhagia. *Am. J. Obstet. Gynecol.* 1993- 169:1134-9.
- Hildlebaugh DA.** Cost and quality-of-life issues associated with different surgical therapies for the treatment of abnormal uterine bleeding. *Obstet. Gynecol. Clin. North Am.* 2000; 27:451-65.
- Hofmann GE, Scott JR, Bergh PA, et al.** Immuno histochemical localization of epidermal growth factor in human endometrium, Decidua and Placenta. *J. Clin. Endocrin. Metab.* 1991; 73:882.
- Hov GG, Skjeldestad FE, Hilstad T.** Use of IUD and subsequent fertility follow up after participation in a randomized clinical trial. *Contraception.* 2007;75:88-92.
- Hubacher D, Lara R, Taylor DJ, et al.** Use of copper intrauterine devices and the risk of tubal infertility among nulligravid women. *N. Eng. J. Med.* 2001;345:561-567.

- Hurk P, O' Brien S.** Non contraceptive use of levonorgestrel-releasing intrauterine system . Hum. Reprod. 1999; 1: 14- 19.
- Hurskainen R, Paavonen J.** Levonorgestrel releasing intrauterine system in the treatment of heavy menstrual bleeding. Curr. Opin. Obstet. Gynecol. 2004; 16:487-490.
- Hurskainen R, Salmi A, Paavonen J. et al.** Expression of sex steroid receptors and Ki-67 in the endometria of menorrhagic women: effects of intrauterine Levonorgestrel. Mol. Hum. Reprod. 2000;11:1013-8.
- Hurskainen R, Teperi J, Paavonen J, et al.** Menorrhagia and uterine artery blood flow. Hum. Reprod. 1999; 14(1): 186-9.
- Hurskainen R, Teperi J, Rissanen P, et al.** Quality of life and cost-effectiveness of levonorgestrel releasing intrauterine system versus hysterectomy for treatment of menorrhagia: a randomised trial. Lancet. 2001;357:273-277.
- Ignar TD, Nelson KG, Bidwell MC, et al.** Coupling of dual signaling pathways: epidermal growth factor action involves the estrogen receptor. Clin. Obstet. Gynecol. 1992; 89: 658-662.
- Irvine GA, Campbell BM, Lumsden MA.** Randomised comparative trial of the levonorgestrel intrauterine system and norethisterone for treatment of idiopathic menorrhagia. Br. J. Obstet. Gynaecol. 1998; 105:592-8.
- Janssen CAH, Scholten PC and Heintz PM.** Reconsidering menorrhagia in gynaecological practice. Is a 30 year old definition still valid? Eur. J. Obstet. Gynecol. Reprod. Biol.1998;78:69-72.

- Janssen CA, Scholten PC, Heintz AP.** A simple visual assessment technique to discriminate between menorrhagia and normal menstrual blood loss. *Clin. Obstet. Gynecol.* 1995; 85:977-82.
- Jarvella I, Tekay A, Jouppila P.** The effect of a Levonorgestrel releasing intrauterine system on uterine artery blood flow, hormone concentrations and ovarian cyst formation in fertile women. *Hum. Reprod.* 1998; 12: 3379-83.
- Jones K, Georgiou M, Hayatt D, et al.** Endometrial adenocarcinoma following the insertion of a Mirena IUCD *Gynecol. Oncol.* 2002;87:216-218.
- Jones RL, Salamonsen LA, Critchly HO, et al.** Inhibin and activin subunits are differentially expressed in endometrial cells and leukocytes during the menstrual cycle, in early pregnancy and in women using progestin-only contraception. *Mol. Hum. Reprod.* 2000; (12): 1107-17.
- Julia O, Hilary C.** Menorrhagia mechanisms and targeted therapies. *Curr. Opin. Obstet. Gynecol.* 2005; 17(4):411-8.
- Kammercr DN, Rogers RG.** Endometrial ablation: electrocautery and laser techniques. *Clin. Obstet. Gynecol.* 2000; 43:561-74.
- Kasonde JM.** Effect of ethamsylate and aminocaproic acid on menstrual blood loss in women using intrauterine devices. *Br. Med. J.* 1975; iv: 21-2.
- Kaunitz AM.** Injectable depot medroxyprogesterone acetate contraception: an update for U.S. clinicians. *Contraception.* 1998; 43:73-83.

- Kelleher C, Braude P.** Recent Advances in Gynaecology. Br. Med. J. 1999; 319(7211):689-92.
- Kooy J, Taylor N, Healy D.** Endothelial cell proliferation in the endometrium of women with menorrhagia and in women following endometrial ablation. Hum. Reprod. 1996; 11:1067-72.
- Kovac SR, Christie SJ, Bindbeutel GA.** Abdominal versus vaginal hysterectomy: a statistical model for determining physician decision making and patient outcome. Med. Decis. Making 1991; 11:19-28.
- Lahteenmaki P, Rauramo I, Backman T.** The levonorgestrel intrauterine system in contraception. Clin. Obstet. Gynecol . 2000;65:693-697.
- Lalonade A.** Evaluation of surgical options in menorrhagia. Br. J. Obstet. Gynaecol. 1994; 101, suppl.11, 8-14.
- Landstrom G, Wallin A, Landmark K, et al.** The action of vasoconstrictive agents on human tubal arteries. Hum. Reprod. 1999; 14:151-5.
- Lethaby A, Augood C, Duchitt K.** Nonsteroidal anti-inflammatory drugs for heavy menstrual bleeding (Cochrane Review). The Cochrane Library 2000a, Issue 4. Oxford: Update Software.
- Lethaby AE, Cooke I, Rees M.** Progesterone or progestogen-releasing intrauterine systems for heavy menstrual bleeding. Cochrane Database Syst Rev. 2005-.CD002126.
- Lethaby A, Irvine G, Cameron I.** Cyclical progestogens for heavy menstrual bleeding (Cochrane Review). In the Cochrane Library, 1999 .Oxford, Update software.

Lethaby A, Shepperd S, Cooke I, Farquhar C. Endometrial resection and ablation versus hysterectomy for heavy menstrual bleeding (Cochrane Review). The Cochrane Library 2000d, Issue 4. Oxford: Update Software.

Liddell H. Menorrhagia. Hum. Reprod. 1993 ; 106 :255-7.

Livio M, Mannvcci PM, Vigauo G, et al. Conjugated estrogens for the anagement of bleeding associated with renal failure. New Eng. J. Med. 1986; 315:73.

Lockhat FB, Emembolu JO, Konje JC. The efficacy, side-effects and continuation rates in women with symptomatic endometriosis undergoing treatment with an intra uterine administered progestogen (levonorgestrel): a 3 year follow-up. Hum. Reprod. 2005;20:789-793.

Ludwig J C, Hoppens C L, McManus L M. Modulation of platelet-activating factor (PAF)synthesis and release from human polymorphonuclear leukocytes: role of extracellular albumin. Arch. Biochem. Biophys. 1985; 241: 337-347

Lumsden M, Smith S. Menstruation and menstrual abnormalities. In:Shaw RW, Soutter WP and Stanton SL (Eds), Text book of Gynecology; 1st edition. Churchill Livingstone 1992; 159.

Luukkainen T, Allonen H, Haukkamaa M, et al. Effective contraception with the levonorgestrel-releasing intrauterine device: 12 month report of The European multicenter study. Contraception. 1987;36:169-179.

- Luukkainen T, Pakarinen P, Toivonen J.** Progestin releasing intrauterine systems. *Semin. Reprod. Med.* 2001; 4: 355-65.
- Machan L, Martin M.** Uterine artery embolization to treat uterine fibroids. *Can. Assoc. Radiol. J.* 2001; 52:183-7.
- Magos AL.** Management of menorrhagia *Br. Med. J.* 1990; 300: 1537-8.
- Maia H, Maltez A, Coelho G, et al.** Insertion of mirena after endometrial resection in patients with adenomyosis. *J. Am. Assoc. Gynecol. Laparosc.* 2003;10:512-516.
- Marbaix R, Vekemans M, Galant C. et al.** Circulating sex hormones and endometrial stromelysin-1 at the start of bleeding episodes in Levonorgestrel implant users. *Hum. Reprod.* 2000 suppl 3:120-34.
- March CM.** Bleeding problems and treatment. *Clin. Obstet. Gynecol.* 1998 ; 41(4):928- 939.
- Markee JE.** Menstruation in intraocular endometrial transplants in the rhesus monkey. *Hum. Reprod.* 1940; 28:219-308.
- Marshall JK, Hunt RH.** Hormonal therapy for bleeding gastrointestinal mucosal vascular abnormalities: a promising alternative. *Eur. J. Gastroenterol. Hepatol.* 1997; 9:521-5.
- McKone E, Sheppard BL, Bonnar J.** Uterine histology and menstrual blood loss. *Irish. J. Med. Sci.* 1991; 160:359-60.
- Meyer WR, Walsh BW, Grainger DA, et al.** Thermal balloon and rollerball ablation to treat menorrhagia: a multicenter comparison. *Obstet. Gynecol.* 1998;92:98-103.

- Miller RM, Frank RA.** Zoladex (Goserelin) in the treatment of benign gynecological disorders: an overview of safety and efficacy. *Br. J. Obstet. Gynaecol.* 1992; 99: 37-41.
- Milne SA, Jabbour HN.** Prostaglandin F₂ α receptor expression and signaling in human endometrium: role of PGF₂ α in epithelial cell proliferation. *J. Clin. Endocrinol. Metab.* 2003; 88 (4): 1825-32.
- Mishell DR.** Noncontraceptive health benefits of oral steroidal contraceptives. *Am. J. Obstet. Gynecol.* 1982; 142:809-816.
- Mohllajee AP, Curtis KM, Peterson HB.** Does insertion and use of an intrauterine device increase the risk of pelvic inflammatory disease among women with sexually transmitted infection? A systematic review. *Contraception.* 2006;73:145-153.
- Montaz M, Zayed M, Rashid K.** Doppler study of the uterine artery in patients using an intrauterine contraceptive device. *Ultrasound Obstet. Gynecol.* 1994; 4:231-4.
- Montz FJ, Bristow RE, Bovicelli A, et al.** Intrauterine progesterone treatment of early endometrial cancer. *Am. J. Obstet. Gynecol.* 2002;186:651-657.
- Munro MG.** Medical management of abnormal uterine bleeding. *Obstet. Gynaecol. Clin. North Am.* 2000; 27:287-304.
- Murphy AA, Kettel LM, Morales AJ.** Regression of uterine leiomyoma in response to anti-progesterone RU 486. *J. Clin. Endocrinol. Metab.* 1993; 76:513-7.

- Ndumbe FM, Husemeyer RP.*** Endometrial adenocarcinoma in association with a levonorgestrel releasing intrauterine system (Mirena). *J. Fam. Plann. Reprod. Health Care.* 2006;32:113-114.
- Need JA, Forbes KL, Milazzo L, et al.*** Danazol in the treatment of menorrhagia: the effect of a 1 month induction dose (200mg) and 2 month's maintenance therapy (200 mg, 100 mg, 50 mg or placebo). *Br. J. Obstet. Gynaecol.* 1992; 32:346-52.
- Neven P, De Muylder X, Van Belle Y, et al.*** Tamoxifen and the uterus. *Br. Med. J.* 1994; 309: 1313-1314.
- Nilsson CG, Lahteenmaki PL, and Luukkainen T.*** Sustained intrauterine release of levonorgestrel over five years. *Fertil. Steril.* 1986; 45: 805-807
- Nilsson L, Rybo G.*** Treatment of menorrhagia. *Am. J. Obstet. Gynecol.* 1971; 110:713-720.
- Nitu-Whalley IC, Lee CA*** Acquired von willebrand's syndrome report of 10 cases and review of the literature. *Haemophilia* 1999; 5:318-26.
- Ojutiku D, Cutner A, Rymer J.*** Ectopic pregnancy with levonorgestrel releasing intrauterine system. *Br. J. Fam. Plan.* 1998; 24 (2): 85-6.
- Pakarinen P, Toivonen J, Luukkainen T.*** Therapeutic use of the levonorgestrel intrauterine system, and counseling . *Semin. Reprod. Med.* 2001, (4): 367-72.
- Perino A, Quartararo P, Catinella E, et al.*** Treatment of endometrial hyperplasia with levonorgestrel releasing intrauterine devices. *Acta. Eur. Fertil.* 1987; 18:137-140.

- Petrucco OM, Fraser IS.** The potential for the use of GnRH agonist for treatment of dysfunctional uterine bleeding. *Br. J. Obstet. Gynaecol.* 1992; Suppi 7:34-6.
- Petta CA, Ferriani RA, Abrao MS, et al.** Randomized clinical trial of a levonorgestrel-releasing intrauterine system and a depot GnRH analogue for the treatment of chronic pelvic pain in women with endometriosis. *Hum. Reprod.* 2005;20:1993-1998.
- Pickles VR, Hall WJ, Best FA, et al.** Prostaglandins in endometrium and menstrual fluid from normal and dysmenorrhoeic subjects. *J. Obstet. Gynaecol. Br. Commonw* 1965; 72: 185-192.
- Prentice A .** Medical management of menorrhagia. *Br. Med. J.* 1999 ; 319:1343-5.
- Preston JT, Cameron IT, Adams EJ, et al.** Comparative study of tranexamic acid and norethisterone in the treatment of ovulatory menorrhagia. *Br. J. Obstet. Gynaecol.* 1995; 102; 401-406.
- Quinn M, Neale BJ, Fortune DW.** Endometrial carcinoma in premenopausal women: a clinicopathological study. *Gynecol. Oncol.* 1985; 20: 298-306.
- Radesie B, Sharma A.** Levonorgestrel releasing intrauterine system for treating menstrual disorders: a patient satisfaction questionnaire. *Br. J. Obstet Gynaecol* 2004; 44 (3): 247-51.
- Rankin GLS, Veall N, Huntsman RG, et al.** Measurement with chromium of red cell loss in menorrhagia. *Lancet* 1962; 1:567-9.
- Raudaskosi TH, Tomas EI, Paakkari IA, et al.** Serum lipids and lipoproteins in post-menopausal women receiving transdermal

oestrogen in combination with a Levonorgestrel releasing intrauterine device. *Maturitas* 1995; 22: 47-53.

Rees MC, Anderson AB, Demers LM, et al. Endometrial and myometrial prostaglandin release during the menstrual cycle in relation to menstrual blood loss. *J. Clin. Endocrinol. Metab.* 1984; 58:813-8.

Rees MC, Parry DM, Anderson AB, et al. Immunohistochemical localization of cyclooxygenase in the human uterus. *Prostaglandins* 1982; 23: 207-214.

Reid PC, Coker A, Coltart R. Assessment of menstrual blood loss using a pictorial chart: a validation study. *Br. J. Obstet. Gynaecol.* 2000; 107:320-2.

Rock G, Adamkiemcz T, Blanchette V. Acquired von willebrand's factor deficiency during high-dose infusion of recombinant factor VIII. *Br. J. Haematol.* 1996; 93:684-7.

Rodgers GM and Bithell TC. Disorders of hemostasis and coagulation. In: Lee. GR, Foerster J, Lukens J, Paraskevas F, Greer JP, Rodgers GM (eds), *Clinical Hematology*, 10th edition, Williams and Wilkins, Awaverly company 1999; 1694.

Rogers PA, Lederman F, Taylor N. Endometrial microvascular growth in normal and dysfunctional states. *Hum. Reprod.* 1998; 4:503-8.

Rogovskaya S, Rivera R, Grimes DA, et al. Effect of a levonorgestrel intrauterine system on women with type 1 diabetes: a randomized trial. *Obstet. Gynecol.* 2005;105:811-815.

- Ronnerdag M, Odland V.** Health effects of long term use of intrauterine Levonorgestrel releasing system. A follow up study over 12 years of continuous use. *Acta. Obstet. Gynecol. Scand.* 1999; 78: 716-721 .
- Rose EH, Aledort LM.** Nasal spray desmopressin for mild haemophilia and von willbrand disease. *Am. Intern. Med.* 1991;114:563.
- Rosenberg MJ, Foldes R, Nishell J, et al.** Performance of the Tcu 380A and Cu-fix IUD's in an international randomized trial. *Contraception* 1996; 53: 197.
- Scarselli G, Tantini C, Colafranceschi M, et al.** Levonorgestrel IUCD and precancerous lesions of the endometrium. *Eur. J. Gynaecol. Oncol.* 1988;9:284-286.
- Sculpher MJ, Dwyer N, Byford S.** Randomised trial comparing hysterectomy and transcervical endometrial resection: effect on health related quality of life and costs two years after surgery *Br. J. Obstet. Gynaecol.* 1996; 103: 142-9.
- Senior J, Sangha R, Baxter GS, et al.** In vitro characterisation of prostanoid FP, DP, IP and TP receptors on the non-pregnant human myometrium. *Br. J. Pharmacol.* 1992; 107:215- 21.
- Sharkey AM, Day K, McPherson A. et al.** Vascular endothelial growth factor expression in human endometrium is regulated by hypoxia. *J. Clin. Endocrinol. Metab.* 2000; 85:402-9.
- Sharma SC, Sheppard BL, Bonnar J.** Relationship of menstrual blood loss with uterine 6-keto- PGF1 and TXB2 levels in women with normal and dysfunctional uterine bleeding. *Irish. J. Med. Sci.* 1990; 159: 57.

- Sharma SC, Sheppard BL, Bonnar J.** Endometrial tissue levels of PGE2 and PGF2 metabolites in women with normal menstruation and dysfunctional uterine bleeding. *Irish. J. Med. Sci.* 1990; 159; 152.
- Shaw RW.** Assessment of medical treatments for menorrhagia: Introduction. *Br. J. Obstet. Gynaecol.* 1994; 101 :15-8.
- Shaw RW, Fraser HM.** Use of a superactive luteinizing hormone releasing hormone agonist in the treatment of menorrhagia. *Br. J. Obstet. Gynaecol.* 1984; 91:913-6.
- Shaw ST, Maeaulay LK.** Morphologic studies on IUCD induced metrorrhagia . Surface changes of the endometrium and microscopic localization of bleeding sites. *Contraception* 1979; 19(1): 63-81.
- Sheppard BL.** The Pathology of dysfunctional uterine bleeding. *Clin. Obstet. Gynecol.* 1984; 11:227-38.
- Sheppard BL, Dockeray CJ, Bonnar J.** An ultrastructural study of menstrual blood in normal menstruation and dysfunctional uterine bleeding. *Br. J. Obstet. Gynaecol.* 1983; 90: 259-265.
- Shoupe D, Meme D, Mezro G, et al.** Prevention of intrauterine hyperplasia in postmenopausal women with intrauterine progesterone. *N. Engl. J. Med.* 1991; 325: 1811-1821.
- Sheth SS and Allahbadia GN.** Diagnosis of dysfunctional uterine bleeding. In: Sheth SS and Sutton CJ (Eds). *Menorrhagia*, 1st edition, Isis Medical Media 1999; 23-43.
- Singer A, Ikomi A.** Successful treatment of fibroids using an intrauterine progesterone device. *Acta. Obstet. Gynecol. Scand.* 1994; 75: 124-130.

Sivin I and Stern J. Health during prolonged use of levonorgestrel 20 micrograms/ day, and the copper T-cu 380 Ag intrauterine contraceptive devices: a multicentre study. International Committee for Contraception Research. Fertil. Steril. 1994; 61: 70-77.

Sivin I, Stern J, Diaz J, et al. Two years of intrauterine contraception with levonorgestrel and with copper: a randomized comparison of the T-Cu 380 Ag and levonorgestrel 20 mcg/day devices. Contraception. 1987;35:245-255.

Smith SJ. Uterine fibriod embolisation. Am. Fam. Physician. 2000;61(12):3601-11.

Smith SK. The pathophysiology of menorrhagia. In: Cameron IT, Fraser IS. Smith S K (eds) Clinical disorders of the endometrium and the menstrual cycle. Oxford: Oxford University Press, 1998:105-115.

Smith SK, Kelly RW. Effect of platelet activating factor on the release of PGF2 and PGE2 by separated cells of human endometrium. J. Reprod. Fertil. 1988; 82: 271-276.

Sowter MC, Singla AA, Lethaby A . Pre-operative endometrial thinning agents before hysteroscopic surgery for heavy menstrual bleeding (Cochrane Review). The Cochrane Library 2000, Issue 4. Oxford: Update Software.

Soysal S, Soysal ME. The efficacy of levonorgestrel-releasing ntrauterine device in selected cases of myoma-related menorrhagia: a prospective controlled trial. Gynecol. Obstet. Invest. 2005;59:29-35.

Speroff L, Fritz MA. Reproductive physiology, menstrual disorders, dysfunctional uterine bleeding. Clinical Gynecologic

Endocrinology and infertility, 7th Ed Baltimore: Lippincott Williams & Wilkins, 2005: 113-129, 331.499-9.

Speroff L, Fritz MA. The Uterus. In: Weinberg (ed), Clinical Gynaecologic Endocrinology And Infertility, 7th edition. Baltimore: Lippincott Williams & Wilkins 2005a; 113-44.

Speroff L, Fritz MA. Dysfunctional uterine bleeding. In: Weinberg (ed), Clinical Gynaecologic Endocrinology And Infertility, 7th edition. Baltimore: Lippincott Williams & Wilkins. 2005b; 547-72.

Speroff L, Glass RH, Kase NG. Dysfunctional uterine bleeding. In: Speroff L, Glass RH, Kase NG, editors. Clinical gynaecologic endocrinology and fertility. 5th edition. Baltimore: Lippincott Williams & Wilkins 2005 : 575-93.

Stanford JB, Mikolajczyk RT. Mechanisms of action of intrauterine devices: update and estimation of postfertilization effects. Am. J. Obstet. Gynecol. 2002; 187: 1699-1708.

Stenchever MA, Droegmueller W, Herbst AL, et al. Comprehensive gynecology. 4th ed. Philadelphia: Mosby 2001;1079-1097.

Stewart E, Novak R. Leiomyoma related bleeding: a classic hypothesis updated for the molecular era. Hum. Reprod. Update 1996; 2:295-306.

Studd J. Shifting indications for hysterectomy. Lancet 2002; 345: 388.

Sturridge F, Guillebaud J. Gynaecological aspects of the levonorgestrel releasing intrauterine system. Br. J. Obstet. Gynaecol.1997; 104: 285-289 .

- Suhonen SP, Holmstrom T, Allonen HO, et al.** Intrauterine and subdermal progestin administration in postmenopausal hormone replacement therapy. *Fertil. Steril.* 2002; 63: 336-342.
- Suvanto LE, Kauppila A.** The levonorgestrel intrauterine system in menopausal hormone replacement therapy: five – year experience. *Fertil. Steril.* 1999; 72: 161-163.
- Swartz DP, Butler WJ.** Normal and abnormal uterine bleeding. In: Thompson JD, Rock JA, editors. *Te Linde's operative gynecology.* 7th edition. Philadelphia: J.B. Lippincott Company, 1992:297-316.
- Tang GW, Lo SS.** Levonorgestrel intrauterine device in the treatment of menorrhagia in Chinese women: efficacy versus acceptability. *Contraception* 1995; 51: 231-5.
- Tewari R, Kay VJ.** Compliance and user satisfaction with the intra-uterine contraceptive device in family planning service. *Eur. J. Contracept. Reprod. Health Care.* 2006;11:28-37.
- Thomas EJ, Okuda KJ, Thomas NM.** The combination of a depot gonadotrophin releasing hormone agonist and cyclical hormone replacement therapy for dysfunctional uterine bleeding. *Br. J. Obstet. Gynaecol.* 1996; 103:18-21.
- Troche V, O'Connor DM, Schaudies RP.** Measurement of human epidermal growth factor receptor in the endometrium during the menstrual cycle. *Am. J. Obstet. Gynecol.* 1991;165:1499.
- Tillson SA, Marian M, Hudson R, et al.** The effect of intrauterine progesterone on hypothalamo-hypophyseal-ovarian axis in humans. *Contraception* 1975; 11(2):179-192.

Turnbull AC, Rees MC. Gestrinone in the treatment of menorrhagia. Br. J. Obstet. Gynaecol. 1990; 97:713-5.

Van Eijkeren M, Christiaens G, Haspels A, et al. Measured menstrual blood loss in women with a bleeding disorder or using oral anticoagulant therapy. Am. J. Obstet. Gynecol. 1990; 162:1261-3.

Van Eijkeren MA, Christiaens GC, Scholten PC. Menorrhagia: Current drug treatment concepts. Drugs 1992; 43:201-9.

Van Houdenhoven K, van Kaam KJ, van Grootheest AC, et al. Uterine perforation in women using a levonorgestrel-releasing intrauterine system. Contraception. 2006;73:257-260.

Vargraftig BB, Fouque F, Beneniste J. Adrenaline and PAF-acether synergise to trigger cyclooxygenase-independent activation of plasma free human platelets. Hum. Reprod. 1982; 28:557-573

Varila E, Wahlstrom T, Rauramo I. A 5-year follow up study on the use of Levonorgestrel intrauterine system in women receiving hormone replacement therapy. Fertil. Steril. 2001; 76 (5): 969-73.

Varma R, Sinha D, Gupta JK. Non-contraceptive uses of levonorgestrel releasing hormone system -a systematic enquiry and overview. Eur. J. Obstet. Gynecol. Reprod. Biol. 2006; 125:9-28.

Varol N, Healey M, Tang P, et al. Ten- year review of hysterectomy morbidity and mortality: can we change direction? Am. J. Obstet. Gynecol. 2001; 41:295-302.

Vasilenko P, Kraicer PF, Kaplan R. A new and simple method of measuring menstrual blood loss. J. Reprod. Med. 1988; 33:293-97.

- Vercellini P, Aimi G, Panazza S, et al.** A levonorgestrel-releasing intrauterine system for the treatment of dysmenorrhea associated with endometriosis: a pilot study. *Fertil. Steril.* 1999;72:505-508.
- Vercellini P, Frontino G, De Giorgi O, et al.** Comparison of a levonorgestrel-releasing intrauterine device versus expectant management after conservative surgery for symptomatic endometriosis: a pilot study. *Fertil. Steril.* 2003;80:305-309.
- Vereide AB, Arnes M, Straume B, et al.** Nuclear morphometric changes and therapy monitoring in patients with endometrial hyperplasia; a study comparing effects of intrauterine levonorgestrel and systemic medroxyprogesterone. *Gynecol. Oncol.* 2003;91:526-533.
- Vessay M, Huggins G, Lawless M, et al.** Tubal sterilization: findings in a large prospective study. *Br. J. Obstet. Gynaecol.* 1993; 90: 203-209.
- Vessey MP, Lawless M, McPherson K, et al.** Fertility after stopping use of intrauterine contraceptive device. *Br. Med. J.* 1983;286:106.
- Vilos GA, Lefebvre G, Graves GR.** Lignes directrices sur la prise en charge du saignement uterin anormal. *J. Obstet. Gynaecol.* 2001,23:710-6.
- Walthen PL, Henderson MC, Witz CA.** Abnormal uterine bleeding. *Med. Clin. North Am.* 1995; 79:329-342.
- Weeks AD and Duffy SR.** Abnormal uterine bleeding: diagnosis and management. In: Stud J (ed), *progress in Obstetrics and Gynecology.* Churchill Livingstone 1996; 12:304-23.
- Weston G, Rogers PA.** Endometrial angiogenesis. *Clin. Obstet. Gynecol.* 2000; 14:919-36.

- WHO.** Medical eligibility criteria for contraceptive use. World Health Organization ; 2004. Available at: [http : // www. who.int/ reproductive - health/ publications /mec/7 iud.pdf](http://www.who.int/reproductive-health/publications/mec/7_iud.pdf) . Accessed January 10, 2007.
- WHO.** Cardiovascular diseases and use of oral and injectable progestogen only contraceptives. Results of an international multicentre, case control study. *Contraception* 1998; 57:315-324.
- Wildemeersch D, Dhont M.** Treatment of nonatypical and atypical endometrial hyperplasia with a levonorgestrel releasing intrauterine system. *Am. J. Obstet. Gynecol.* 2003,188:1297-1298.
- Wildemeersch D, Batar I, Webb A, et al.** The frameless intrauterine contraceptive implant- an update for interval,emergency and post abortal contraception. *Br. J. Fam. Plan.* 1999; 24: 149.
- Williams P, Warwick R, Dyson M, eds.** Gray's anatomy. 37th edition.Edinburgh: Churchill Livingstone, 1989: 852.
- Wolter SL, Stadberg E, Andersson K, et al.** Intrauterine administration of levonorgestrel 5 and 10 micrograms/24 hours in perimenopausal hormone replacement therapy. A randomized clinical study during one year. *Acta. Obstet. Gynaceol. Scand.* 1997; 76 (5): 449-54.
- Working Party for Guidelines for the Management of Heavy Menstrual Bleeding .** An evidence based guideline for the management of heavy menstrual bleeding , *Br. Med . J.*1999; 112:1747.
- Worthington KR.** Anatomy of the uterine artery. *Am. J. Roentgenol.* 2000; 174:258.

Xiao B, Zeng T, Wu S, et al. Effect of levonorgestrel-releasing intrauterine device on hormonal profile and menstrual pattern after long term use. *Contraception*. 1995;51:359- 365.

Zinger M, Thomas MA. Using the levonorgestrel intrauterine System. *Am. J. Obstet. Gynecol.* 2001; 2: 11-20.